Cancer immunotherapy by adenosinergic CD39 and CD73 as emerging immune checkpoints

作者：Xinyu Yin, Ying Yang, Songjiang Liu · 发表于：Discover Oncology · 年份：2025 · DOI：10.1007/s12672-025-04001-0 · 被引用次数：6 · 研究领域：Adenosine and Purinergic Signaling、Nanoplatforms for cancer theranostics、Click Chemistry and Applications

Extracellular adenosine has recently been identified as an immunological checkpoint mediator that hinders the immune response to malignancies. The production of adenosine is facilitated by the enzymatic activity of CD39 and CD73. There is an increasing body of evidence suggesting that CD39 and CD73, which are considered to be emerging immunological checkpoints, can transform adenosine triphosphate (ATP)-mediated pro-inflammatory tumor microenvironment (TME) into an adenosine-mediated immunosuppressive through purinergic pathway. The aim of this study was to review macrophages-based cancer immunotherapy by adenosinergic CD39 and CD73 as emerging immune checkpoints. We searched the PubMed, EMBASE, Web of Science, and Medline (Ovid) databases to find relevant studies between December 30, 2010, and December 30, 2024. The search strategy encompassed utilization of Cancer, Immune checkpoints, CD39, CD73, Immunotherapy as keywords. The case reports, reviews, evaluations, originals, and earlier meta-analyses were all included in the study. The inclusion criteria were the researches that investigated the functions of the adenosinergic immunological checkpoints CD39 and CD73 in cancer immunotherapy. Clinical studies have examined small molecule inhibitors or monoclonal antibodies that target the CD39/CD73 pathway in recent years. Cancer immunotherapy might profit from therapeutic inhibition of CD39 and CD73’s enzymatic activity, given that these two proteins are crucial for the convers...